IND Swift Limited Pioglitazone Export Data — India (DGFT 2022–2026)

Name: IND Swift Limited Pioglitazone Export Records India — #7 Exporter, 55 Shipments, $1.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Pioglitazone

India Pharmaceutical Trade Intelligence

$37.3M115 Suppliers70 CountriesHS 30049099

ExportsIndia → UNITED STATES60.5%India → PHILIPPINES7.8%

ImportsUNITED STATES → India$30.6K BRAZIL → India$4.5K

#1 Buyer: RISING PHARMA

IND Swift Limited — Pioglitazone Exporter #7 | $1.2M Trade Value | TransData Nexus | TransData Nexus

IND Swift Limited — Pioglitazone Exporter Profile

Indian Pharmaceutical Exporter · #7 for Pioglitazone · $1.2M export value · DGFT Verified

IND Swift Limited is the #7 Indian exporter of Pioglitazone with $1.2M in export value and 55 verified shipments. IND Swift Limited holds a 3.3% market share in Pioglitazone exports across 8 countries. The company exports 13 pharmaceutical products worth $36.7M across 9 therapeutic categories.

IND Swift Limited — Pioglitazone Export Profile: Buyers & Destinations

IND Swift Limited Pioglitazone export treemap — buyers and destination countries | TransData Nexus

Where Does IND Swift Limited Export Pioglitazone?

Country	Value	Shipments	Share
UNITED ARAB EMIRATES	$422.6K	15	41.1%
QATAR	$408.7K	12	39.7%
AUSTRALIA	$134.1K	9	13.0%
HONG KONG	$26.1K	10	2.5%
PHILIPPINES

Who Are the Top Buyers of Pioglitazone from IND Swift Limited?

Buyer	Country	Value	Orders
NEW COUNTRY HEALTHCARE LLC	UNITED ARAB EMIRATES	$357.0K	8
WELL CARE TRADING W.L.L	QATAR	$307.7K	8
WELL CARE TRADING W L L	QATAR	$70.4K	3
APOTEX PTY LTD	AUSTRALIA	$68.9K	5
LIFE PHARMA FZE	UNITED ARAB EMIRATES	$65.6K	7
APOTEX PTY LTD.	AUSTRALIA	$53.2K	3
WELL CARE TRADING	QATAR	$30.7K	1
MEDINOVA PHARMACEUTICAL INC.	PHILIPPINES	$18.9K	2
CHAMPION HEALTHCARE LTD.	HONG KONG	$17.8K	4
APOTEX PTY LIMITED	AUSTRALIA	$12.0K	1

IND Swift Limited supplies Pioglitazone to 15 buyers globally. The largest buyer is NEW COUNTRY HEALTHCARE LLC (UNITED ARAB EMIRATES), followed by WELL CARE TRADING W.L.L (QATAR) and WELL CARE TRADING W L L (QATAR). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Pioglitazone Formulations Does IND Swift Limited Export?

Product Description / Formulation	Value	Shipments
GLIT 30MG (PIOGLITAZONE TABLETS USP 30MG	$150.0K	3
GLIT 15MG (PIOGLITAZONE TABLETS USP 15MG	$100.0K	2
APOTEX PIOGLITAZONE 45 MG,(Pioglitazone	$53.2K	3
GLIT 15 (PIOGLITAZONE TABLETS- 15 MG) BATCH NO: ASW10125,ASW10225, MFG: JAN2025EXP: DEC2027	$52.9K	2
GLIT 30MG(PIOGLITAZONE TABLETS USP 30 MG	$50.0K	1
GLIT 30MG(Pioglitazone Tablets-30mg),BT#	$50.0K	1
GLIT 15MG,(Pioglitazone Tablets-15mg),BT	$50.0K	1
GLIT 30 MG(PIOGLITAZONE TABLETS-30MG)7168X2X14T BATCH NO.: WH10124 MFG: JAN 2024EXP: DEC 2026	$50.0K	1
GLIT 15MG(PIOGLITAZONE TABLETS USP 15 MG	$45.2K	1
GLIT 15 MG(PIOGLITAZONE TABLETS-15MG)7296X2X14T BATCH NO.: WG10124 MFG: JAN 2024EXP: DEC 2026	$40.7K	1

IND Swift Limited exports 45 distinct Pioglitazone formulations including tablets, capsules, syrups, and combination drugs. The top formulation is GLIT 30MG (PIOGLITAZONE TABLETS USP 30MG with 3 shipments worth $150.0K.

How Does IND Swift Limited Compare to Nearest Pioglitazone Exporters?

Exporters ranked immediately above and below #7 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
5	AJANTA PHARMA LIMITED	$1.8M	36	2	$48.9K
6	MICRO LABS LIMITED	$1.6M	98	9	$15.9K
7	IND SWIFT LIMITED ★	$1.2M	55	8	$22.2K
8	MACLEODS PHARMACEUTICALS LIMITED	$1.2M	106	1	$11.5K
9	ARISTO PHARMACEUTICALS PRIVATE LIMITED	$721.0K	100	6	$7.2K

IND Swift Limited ranks #7 among 115 Indian Pioglitazone exporters. Average shipment value of $22.2K compared to the market average of $305.7K. The closest competitors by value are AJANTA PHARMA LIMITED and MICRO LABS LIMITED.

Which Indian Ports Ship Pioglitazone Exports?

Port	Shipments	% Share
DELHI AIR	249	9.3%
HYDERABAD ICD	229	8.6%
DELHI AIR CARGO ACC (INDEL4)	206	7.7%
SAHAR AIR	205	7.7%
HYDERABAD ICD (INSNF6)	203	7.6%
SAHAR AIR CARGO ACC (INBOM4)	143	5.3%
MUNDRA SEA	127	4.7%
CMA CGM LOGISTICS PARK ICD	126	4.7%

Geopolitical & Trade Policy Impact on IND Swift Limited's Pioglitazone Exports

Ind-Swift Laboratories' export operations have been influenced by recent geopolitical developments. The Israel-Iran conflict has heightened security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and increased freight rates by 40–50% on key India–Europe routes, impacting the company's logistics and cost structures. (livemint.com)

Conversely, the India–European Union Free Trade Agreement (India–EU FTA), concluded in January 2026, is poised to benefit Indian pharmaceutical exporters. The agreement eliminates tariffs on most European pharmaceutical imports, enhancing the competitiveness of Indian products in the EU market. This development presents an opportunity for Ind-Swift Laboratories to expand its footprint in Europe. (en.wikipedia.org)

In the United States, the reshoring of pharmaceutical manufacturing and potential imposition of tariffs on imports pose challenges for Indian exporters. While there are currently no import duties on Indian pharmaceutical products entering the US, the introduction of tariffs could affect the profitability of low-margin generic drugs, potentially leading to market exits. (cfo.economictimes.indiatimes.com)

IND Swift Limited — Regulatory Compliance & Quality Standards

Compliance with international regulatory standards remains paramount for Indian pharmaceutical exporters. Ind-Swift Laboratories has demonstrated a commitment to quality by adhering to Good Manufacturing Practices (GMP) as stipulated by the US FDA, WHO, and EU authorities. The company's manufacturing facilities in Punjab and Jammu have been inspected and approved by these regulatory bodies, facilitating access to regulated markets.

The evolving regulatory landscape, including the EU's Falsified Medicines Directive, necessitates continuous investment in quality systems and supply chain transparency. Ind-Swift Laboratories' focus on high-margin formulations underscores the importance of maintaining stringent quality standards to meet global regulatory requirements and sustain market access.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Pioglitazone shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: IND Swift Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 55 individual customs records matching IND Swift Limited exporting Pioglitazone, covering 45 formulations to 8 countries via 15 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 70+ countries, 293+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Pioglitazone

Pioglitazone

IND Swift Limited — Pioglitazone Exporter Profile

IND Swift Limited — Pioglitazone Export Profile: Buyers & Destinations

Where Does IND Swift Limited Export Pioglitazone?

Who Are the Top Buyers of Pioglitazone from IND Swift Limited?

What Is India's Total Pioglitazone Export Value and How Much Does IND Swift Limited Contribute?

What Is the Average Shipment Value for IND Swift Limited's Pioglitazone Exports?

How Does IND Swift Limited Compare to Other Indian Pioglitazone Exporters?

What Pioglitazone Formulations Does IND Swift Limited Export?

Regulatory Requirements: Exporting Pioglitazone to Key Markets

Australia — TGA

How Does IND Swift Limited Compare to Nearest Pioglitazone Exporters?

Which Indian Ports Ship Pioglitazone Exports?

Geopolitical & Trade Policy Impact on IND Swift Limited's Pioglitazone Exports

IND Swift Limited — Regulatory Compliance & Quality Standards

About IND Swift Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Pioglitazone Export Data from IND Swift Limited

Pioglitazone Stats

Company Overview

Top Products by IND Swift Limited

Related Analysis

Need Detailed Export Data?

Data Source